U.S. Senator Elizabeth Warren (D-MA) was awarded a 5-Star rating from Prescription Justice for her full support of the Prescription Justice Policy Platform. These are commonsense and necessary policies to lower drug prices here at home and expand access to lower cost medication from pharmacies in other countries.
Prescription Justice assigns ratings to members of Congress based on their support of the organization’s policy platform. The Prescription Justice Policy Platform is based on the reality that America is suffering from a crisis of high drug prices. (more…)
We are pleased to announce that U.S. Senator Angus King (I-ME) has received the Prescription Justice 5-star rating based on his full support of the organization’s Policy Platform to lower drug prices here and expand access to safe and affordable medication from other countries. Senator King’s 5-star rating reflects his unwavering support of commonsense policy solutions to end the prescription drug affordability crisis. Members of Congress get one star for their positions on the following:
1. Recognizes that the United States is suffering from a crisis of high drug prices?
2. Ending the ban that prevents Medicare from negotiating lower drug prices with pharmaceutical companies;
3. Making reverse payment arrangements between brand and generic companies, also known as “pay-for-delay” illegal;
4. Legalizing the importation of lower-cost medication from Canada and other countries with similarly strict pharmaceutical regulations; and
5. Using reasonable, commonsense, and compassionate enforcement discretion to permit individuals to import small quantities of affordable medication to fill prescriptions. (more…)
Prescription Justice has endorsedRyan Watts for the U.S. House of Representatives in the 6th District of North Carolina based on his pro-patient/pro-consumer stance to address the prescription drug price crisis in America.
Ryan Watts fully supports the Prescription Justice Policy Platform to permit Medicare to negotiate drug prices; ending “pay-for-delay” deals by pharmaceutical companies that prevent lower cost generics from coming to market; legalizing importation of lower-cost and safe medication; and expressly permitting personal importation now from licensed pharmacies as a lifeline of affordable medication. (more…)
Last Friday, President Trump unveiled his blueprint to lower drug prices named American Patients First. Sadly, the Administration’s plan excludes Trump’s campaign promises to use the massive buying power of the government's Medicare program to negotiate lower prices for older Americans and provide greater access to imported, lower-cost medications. (more…)
As President Donald Trump gives his big speech on drug prices today, we're going to highlight a young candidate for U.S. Congress who is clearly on the side of the people on the issue of drug prices. Ryan Watts, Democratic candidate for Congress in the 6th District of North Carolina, became the first candidate to complete the Prescription Justice Drug Prices Policy Platform Questionnaire, a national bipartisan effort to provide members of Congress and candidates for statewide and federal offices an opportunity to state their position on the Prescription Justice policy platform. (more…)
Prescription Justice recently joined with nine other health, social justice and consumer advocacy organizations to launch a petition to demand Congress act to bring relief to the millions of Americans who can't afford the prescription drugs they need.
The online petition largely echoes the Prescription Justice policy platform which prioritizes ending the ban on Medicare negotiating drug prices, making pay-for-delay deals illegal, and permitting wider access to lower-cost, imported medication through legislative, regulatory, and policy reforms. (more…)
As we leave 2017 behind, the crisis of high prescription drug prices continues to threaten the health and well-being of Americans who struggle to access life-saving medications. Millions of Americans are forced to choose between taking the medicine they need, paying the rent or buying food for their families; tens of millions don't take prescribed medication; and federal and state budgets are overwhelmed. At Prescription Justice, we are dedicated solely to putting an end to this devastating crisis.
Over the past year, we have concentrated our efforts and resources on advocating for regulatory and legislative reforms and commonsense policies to lower domestic drug prices and expand access to lower cost medication from pharmacies in other countries. (more…)
Last week, Gabriel Levitt, founder of Prescription Justice, published an Op-Ed in The Guardian about Alex Azar, President Trump's nominee for Secretary of the Department of Health and Human Services (HHS). Mr. Levitt's Op-Ed, Alex Azar is big pharma personified. He must not become US health secretary, underscores the urgent need for members of Congress to oppose Azar's confirmation.
During recent testimony before the Senate Health, Education, Labor and Pension Committee hearing on Stabilizing the Affordable Care Act Marketplace, AARP became the largest consumer organization to publicly support the prescription drug policy solutions reflected in Prescription Justice’s policy platform. AARP supports commonsense policy reforms to allow Medicare to negotiate drug prices, end pay-for-delay deals that delay entry of generic drugs into the marketplace, and increase access to lower cost medications through safe prescription drug importation. As part of a larger set of priorities for protecting and strengthening the healthcare system, AARP boldly declared that any changes to the healthcare law must include solutions to address rising prescription drug costs. (more…)
We are pleased to announce that Senator Amy Klobuchar (D-MN) recently introduced legislation aimed at lowering the high cost of prescription drugs for the 41 million seniors enrolled in Medicare. If enacted, S. 1688, The Empowering Medicare Seniors to Negotiate Drug Prices Act, would allow the Secretary of Health and Human Services to negotiate fair prescription drug prices under Part D of the Medicare program. The federal government spends far more on prescription drugs purchased for Medicare enrollees than it spends for Medicaid and the Veterans Administration because the current law prohibits Medicare from negotiating lower prices with pharmaceutical companies.
S. 1688 would eliminate the “non-interference” clause in Title XVIII of the Social Security Act, which expressly bans Medicare from negotiating drug prices. The language in S. 1688 is less restrictive than similar legislation, S. 41, also introduced by Sen. Klobuchar earlier this year. That legislation, S. 41, the Medicare Prescription Drug Price Negotiation Act of 2017, would prohibit the Secretary of Health and Human Services from establishing or requiring a fixed drug formulary for any prescription drug plan in Medicare; S. 1688 wisely omits this binding language.(more…)